1. Home
  2. ISD vs EOLS Comparison

ISD vs EOLS Comparison

Compare ISD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PGIM High Yield Bond Fund Inc.

ISD

PGIM High Yield Bond Fund Inc.

HOLD

Current Price

$14.42

Market Cap

490.4M

Sector

Finance

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$7.21

Market Cap

444.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISD
EOLS
Founded
2012
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
490.4M
444.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ISD
EOLS
Price
$14.42
$7.21
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.80
AVG Volume (30 Days)
127.1K
964.5K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
9.69%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$285,823,000.00
Revenue This Year
N/A
$14.36
Revenue Next Year
N/A
$23.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.10
52 Week Low
$10.98
$5.71
52 Week High
$13.17
$17.12

Technical Indicators

Market Signals
Indicator
ISD
EOLS
Relative Strength Index (RSI) 43.36 56.80
Support Level $14.38 $7.05
Resistance Level $14.52 $7.34
Average True Range (ATR) 0.10 0.26
MACD -0.02 0.03
Stochastic Oscillator 6.06 87.84

Price Performance

Historical Comparison
ISD
EOLS

About ISD PGIM High Yield Bond Fund Inc.

PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: